Subscribe
Logo small
Search

AOTMiT: Transparency Council on orthodontics, esophageal cancer and hypertension, among others

MedExpress Team

Medexpress

Published Oct. 3, 2025 07:57

On Monday, October 6, the next meeting of the Transparency Council.
AOTMiT: Transparency Council on orthodontics, esophageal cancer and hypertension, among others - Header image

Agenda:

  1. Preparation of a position on the qualification of the health care service
    • "Standard vestibular plate in orthodontic treatment" from the field of dental treatment.
  1. Preparation of a position paper on the evaluation of the drug Tevimbra (tislelizumabum) under drug program B.58
    • "Treatment of patients with cancer of the esophagus, gastroesophageal junction and stomach (ICD-10: C15-C16)". - 2nd line in monotherapy.
  1. Preparation of a position paper on the evaluation of the drug Tevimbra (tislelizumabum) under drug program B.58
    • "Treatment of patients with cancer of the esophagus, gastroesophageal junction and stomach (ICD-10: C15-C16)." - Esophageal squamous cell carcinoma (ESCC), 1st line.
  1. Preparation of a position paper on the evaluation of the drug Tevimbra (tislelizumabum) under drug program B.58
    • "Treatment of patients with cancer of the esophagus, gastroesophageal junction and stomach (ICD-10: C15-C16)." - HER-2 negative adenocarcinoma, 1st line with ChT, PD-L1 expression ≥5%.
  1. Preparation of a position paper on the evaluation of the drug Pemazyre (pemigatinibum) under drug program B.5
    • "Treatment of patients with hepatocellular carcinoma (ICD-10: C22.0) or biliary tract cancer (ICD-10: C22.1, C23, C24.0, C24.1, C24.8, C24.9)."
  1. Preparation of a position paper on the evaluation of the drug Polpril Plus (ramiprilum + indapamidum)
    • For the indication: treatment of hypertension as replacement therapy in adult patients whose blood pressure is adequately controlled with ramipril and indapamide used separately at the same doses as in the combination product.
  1. Preparation of a position paper on the examination of the legitimacy of issuing reimbursement approvals for the medicinal product Revuforj (revumenib)
    • For the indication: treatment of relapsed or refractory acute leukemia with KMT2A gene translocation.
  1. Preparation of an opinion on the draft health policy program of the local government unit
    • "Health Policy Program on Pneumococcal Vaccination for Persons Over 55 Living in the Municipality of Ustroń for 2026-2030".

Szukaj nowych pracowników

Dodaj ogłoszenie o pracę za darmo

Lub znajdź wyjątkowe miejsce pracy!